SEARCH · PubMed Health

Results for “DUCTUS ARTERIOSUS. PATENT”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources

PubMed1993

Effect of patent ductus arteriosus on Doppler-derived right ventricular systolic time intervals.

Right ventricular systolic time intervals (RVSTI) and noninvasive Doppler-derived pulmonary blood flow were measured before and after surgical ductus ligation in 18 otherwise healthy infants and children who were older than 3 months of age. Right ventricular preejection period (PEP) and the ratio of preejection period and right ventricular ejection time (PEP/RVET), both corrected or uncorrected for heart rate, decreased significantly following surgery (PEP 71 +/- 14 vs. 50 +/- 13, p < 0.001 and PEP/RVET 0.29 +/- 0.06 vs. 0.21 +/- 0.05, p < 0.001). The volume of pulmonary blood flow correlated with PEP/RVET (r = 0.48, p = 0.003). The magnitude of the change in pulmonary blood flow correlated with the change in PEP/RVET (r divided by 0.56, p = 0.016). The velocity of circumferential fiber shortening (VCFc) increased after surgery, but not significantly. We speculate that patent ductus arteriosus has a similar effect on right ventricular performance when other congenital heart defects are present.

Blood Flow Velocity↗

PubMed1984

Patent ductus arteriosus in neonates with severe respiratory disease.

Daily aortic contrast echo studies were carried out in 200 neonates with severe respiratory disease to determine the natural history of the ductus arteriosus during the first days of life and the effect of patency on subsequent morbidity and mortality. Decisions related to surgical or pharmacologic closure of a PDA were not based on the results of the contrast echo studies. The risk that intervention would be required was greater in infants weighing less than 1500 gm (P less than 0.005) and in patients in whom the ductus had not closed spontaneously by day 3 (P less than 0.001) regardless of birth weight. The clinical course in infants with a PDA on the third day of life revealed a lower survival rate (P less than 0.005), a greater requirement for prolonged respiratory support (P less than 0.005), and a higher incidence of bronchopulmonary dysplasia (P less than 0.005) in all birth weight categories. Ductal patency often was not associated with early clinical manifestations. No infant who had a negative echo study on the third day of life subsequently developed signs or symptoms of patent ductus arteriosus. We conclude that patency of the ductus arteriosus is a negative prognostic factor in the severely ill neonate with respiratory distress.

Aorta↗

PubMed2001

Coil occlusion of patent ductus arteriosus associated with right aortic arch.

Two children with patent ductus arteriosus and associated right aortic arch underwent successful transcatheter coil occlusion. Recognition of ductal anatomy and ensuring that no symptomatic vascular ring is present are important prior to embarking on ductal occlusion. It is concluded that coil occlusion of patent ductus arteriosus in association with right aortic arch is feasible, safe, and effective.

Abnormalities, Multiple↗

PubMed1992

Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus.

The aim of this study was to measure plasma atrial natriuretic peptide in preterm infants with a patent ductus arteriosus before and after closure with indomethacin. Atrial natriuretic peptide was measured in 28 preterm infants with clinical and echocardiographic evidence of a patent ductus arteriosus and in eight preterm infants who did not develop clinical evidence of a patent ductus arteriosus. Plasma concentration of atrial natriuretic peptide was measured by radioimmunoassay. In 18 infants the patent ductus arteriosus closed after one course of indomethacin; atrial natriuretic peptide levels decreased from median 1240 pg/ml (range 201-5483 pg/ml) to 266 pg/ml (range 62-1108 pg/ml). In four infants the patent ductus arteriosus closed after two courses of indomethacin and two infants had surgical ligation after indomethacin treatment failed. The patent ductus arteriosus closed spontaneously in four infants (atrial natriuretic peptide median level 152 pg/ml, range 61-495 pg/ml). In the eight infants without patent ductus arteriosus, atrial natriuretic peptide level was median 224 pg/ml (range 38-876 pg/ml). Measurement of plasma atrial natriuretic peptide concentration has a role in predicting when indomethacin treatment is indicated.

Atrial Natriuretic Factor↗

PubMed1952